With 1.39 million shares changed hands, the volume of the stock remained lighter than its average volume of 1.73 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $0.6063 whereas the lowest price it dropped to was $0.4802. The 52-week range on RLMD shows that it touched its highest point at $4.47 and its lowest point at $0.24 during that stretch. It currently has a 1-year price target of $1.00. Beta for the stock currently stands at 0.41.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of RLMD was up-trending over the past week, with a rise of 53.08%, but this was up by 84.83% over a month. Three-month performance surged to 82.01% while six-month performance fell -81.11%. The stock lost -82.89% in the past year, while it has gained 14.81% so far this year. A look at the trailing 12-month EPS for RLMD yields -2.50 with Next year EPS estimates of -0.99. For the next quarter, that number is -0.46. This implies an EPS growth rate of 27.17% for this year and 48.70% for next year. EPS is expected to grow by 31.28% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of 0.68%.
Float and Shares Shorts:
At present, 33.19 million RLMD shares are outstanding with a float of 27.81 million shares on hand for trading. On 2025-04-30, short shares totaled 2.03 million, which was 613.00002 higher than short shares on 1743379200. In addition to Dr. Sergio Traversa M.B.A., Pharm.D. as the firm’s CEO & Director, Mr. Maged S. Shenouda M.B.A., R.Ph. serves as its Chief Financial Officer.
Institutional Ownership:
Through their ownership of 0.39396 of RLMD’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-12-31, RLMD reported revenue of $0.0 and operating income of -$18218435.0. The EBITDA in the recently reported quarter was -$18437118.0 and diluted EPS was -$0.58.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for RLMD since 1 analysts follow the stock currently. There are 0 analysts who recommend BUY ratings, while 1 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With RLMD analysts setting a high price target of 1.0 and a low target of 0.6, the average target price over the next 12 months is 0.86667.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$2.65382 being high and -$2.75284 being low. For RLMD, this leads to a yearly average estimate of -$2.70333.
